These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8994155)

  • 1. Determining transition probabilities from mortality rates and autopsy findings.
    Black WC; Nease RF; Welch HG
    Med Decis Making; 1997; 17(1):87-93. PubMed ID: 8994155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: a study of five common cancers.
    Charvat H; Bossard N; Daubisse L; Binder F; Belot A; Remontet L
    Cancer Epidemiol; 2013 Dec; 37(6):857-63. PubMed ID: 24063904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
    Feuer EJ; Mariotto A; Merrill R
    Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
    Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
    Konety BR; Bird VY; Deorah S; Dahmoush L
    J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.
    Zhu X; Kranse R; Bul M; Bangma CH; Schröder FH; Roobol MJ
    Can J Urol; 2013 Jun; 20(3):6756-60. PubMed ID: 23783043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Louisiana autopsy patterns 1999-2006.
    Andrews-Joseph A; Bourgeois SS; Ratard RC
    J La State Med Soc; 2009; 161(2):97, 99-102. PubMed ID: 19489390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent PSA after prostatectomy for prostate cancer: implications of PSA doubling time.
    Ashley T
    J Insur Med; 2003; 35(3-4):161-4. PubMed ID: 14971088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection.
    Belville WD
    Semin Urol Oncol; 1995 Aug; 13(3):181-6. PubMed ID: 8521130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.
    Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L
    CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Structure and Parameterization of the Breast Cancer Transition Model Among Chinese Women.
    Huang Y; Li Q; Torres-Rueda S; Li J
    Value Health Reg Issues; 2020 May; 21():29-38. PubMed ID: 31634794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the crude probability of death due to cancer and other causes using relative survival models.
    Lambert PC; Dickman PW; Nelson CP; Royston P
    Stat Med; 2010 Mar; 29(7-8):885-95. PubMed ID: 20213719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric estimation of transition probabilities in the non-Markov illness-death model: A comparative study.
    de Uña-Álvarez J; Meira-Machado L
    Biometrics; 2015 Jun; 71(2):364-75. PubMed ID: 25735883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Providing clinicians and patients with actual prognosis: cancer in the context of competing causes of death.
    Howlader N; Mariotto AB; Woloshin S; Schwartz LM
    J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):255-64. PubMed ID: 25417239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bias in Markov models of disease.
    Faissol DM; Griffin PM; Swann JL
    Math Biosci; 2009 Aug; 220(2):143-56. PubMed ID: 19538974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
    Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
    Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer and the Will Rogers phenomenon.
    Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
    J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of modeling to understand the impact of screening on U.S. mortality: examples from mammography and PSA testing.
    Feuer EJ; Etzioni R; Cronin KA; Mariotto A
    Stat Methods Med Res; 2004 Dec; 13(6):421-42. PubMed ID: 15587432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.